Q-omics provides the consensus-scored NUDT19 profile across patient tissues and cancer cell-line models. NUDT19 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NUDT19 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, NUDT19 RNA expression shows 19,107 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BLCA, and UVM as cancer lineages where NUDT19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUDT19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUDT19 survival associations across molecular data types. NUDT19 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUDT19 RNA expression–survival associations across cancer types. High NUDT19 expression shows unfavorable associations in ACC, UVM, LGG, LIHC, UCEC and DLBC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NUDT19 RNA expression.
This table summarizes NUDT19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NUDT19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUDT19 shows higher tumor expression in BLCA, LUSC, COAD, BRCA, UCEC and KIRC. The BLCA box plot shows higher NUDT19 RNA expression in tumor versus normal tissue (log2 FC = +1.359, t-test p < 0.001).
This table shows molecular features associated with NUDT19 in patient tissues and cancer cell lines. In patient samples, NUDT19 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUDT19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and OVARY.
